Regulation of telomeres by mirnas in human cancer



Similar documents
PART 3.3: MicroRNA and Cancer

A role of microrna in the regulation of telomerase? Yuan Ming Yeh, Pei Rong Huang, and Tzu Chien V. Wang

Department of BioScience Technology Chung Yuan Christian University 2015/08/13

Cancer SBL101. James Gomes School of Biological Sciences Indian Institute of Technology Delhi

LESSON 3.5 WORKBOOK. How do cancer cells evolve? Workbook Lesson 3.5

What is Cancer? Cancer is a genetic disease: Cancer typically involves a change in gene expression/function:

CONTRACTING ORGANIZATION: University of Alabama at Birmingham Birmingham, AL 35294

Special report. Chronic Lymphocytic Leukemia (CLL) Genomic Biology 3020 April 20, 2006

micrornas Non protein coding, endogenous RNAs of 21-22nt length Evolutionarily conserved

Relative Quantification of mirna Target mrnas by Real-Time qpcr. 1 Introduction. Gene Expression Application Note No. 4

LightSwitch Luciferase Assay System

Clonetics Conditionally Immortalized Human Cells. Relevant Cells for High Throughput Screening

Introduction. Cancer Biology. Tumor-suppressor genes. Proto-oncogenes. DNA stability genes. Mechanisms of carcinogenesis.

Cancer: Cells Behaving Badly

Translating DNA repair pathways into therapeutic targets: beyond the BRCA1/2 and PARP inhibitor saga. Jorge S Reis-Filho, MD PhD FRCPath

OriGene Technologies, Inc. MicroRNA analysis: Detection, Perturbation, and Target Validation

岑 祥 股 份 有 限 公 司 技 術 專 員 費 軫 尹

Appendix C DNA Replication & Mitosis

PREPARED FOR: U.S. Army Medical Research and Materiel CommandFort Detrick, Maryland

mirnaselect pegp-mir Cloning and Expression Vector

Sommaire projets sélectionnés mesure 29: Soutien à la recherche translationnelle

Telomere Stabilizing Mechanisms

Lezioni Dipartimento di Oncologia Farmacologia Molecolare. RNA interference. Giovanna Damia 29 maggio 2006

Cancer Genomics: What Does It Mean for You?

Update in Hematology Oncology Targeted Therapies. Mark Holguin

MicroRNA signatures in human cancers

Notch 1 -dependent regulation of cell fate in colorectal cancer

Chapter 12: The Cell Cycle

Cancer. 9p21.3 deletion. t(12;21) t(15;17)

Juliana Xu Lorraine J. Gudas, Ph.D. Weill Medical College of Cornell University New York, NY 10021

Problem Set 6 KEY

TEXT PICTURE. Martin Puhr PhD. Medical University of Innsbruck. Department of Urology Division of Experimental Urology

Nuove mutazioni nella leucemia mielomonoci/ca cronica

Dal germinale al somatico nella identificazione di tumori ereditari

New strategies in anticancer therapy

Guided Notes: Chapter 9 Cellular Reproduction

MicroRNA formation. 4th International Symposium on Non-Surgical Contraceptive Methods of Pet Population Control

Cell Division Mitosis and the Cell Cycle

MUTATION, DNA REPAIR AND CANCER

Biomedicine The background. The main interest. The tools

microrna Signatures in Cancer E. ROBERT WASSMAN, MD, FAAP, FACMG CHIEF MEDICAL OFFICER, ROSETTA GENOMICS

EXPRESSION ARREST shrna mir GENOME- WIDE LIBRARIES

Chromosomes, Karyotyping, and Abnormalities (Learning Objectives) Learn the components and parts of a metaphase chromosome.

CCR Biology - Chapter 5 Practice Test - Summer 2012

BioMmune Technologies Inc. Corporate Presentation 2015

LEUKEMIA LYMPHOMA MYELOMA Advances in Clinical Trials

Supplementary Figure 1.

SUPPLEMENTARY DATA 1

Lecture 3: Mutations

Chapter 12: The Cell Cycle

Leukemia Research Foundation Scientific Research Grant Recipients

The Human Genome Project

CURRICULUM VITAE. Tabitha M. Hardy

Identification of CD4+ T cell epitopes specific for the breast cancer associated antigen NY-BR-1

Programme. Michele Grieco Dipartimento di Scienze Ambientali Seconda Università degli Studi di Napoli Naples, Italy

January 23, SCIENTIFIC PROGRAM

treatments) worked by killing cancerous cells using chemo or radiotherapy. While these techniques can

INSERM/ A. Bernheim. Overcoming clinical relapse in multiple myeloma by understanding and targeting the molecular causes of drug resistance

Pathway Analysis : An Introduction

MULTIPLE MYELOMA. Dr Malkit S Riyat. MBChB, FRCPath(UK) Consultant Haematologist

Transfection-Transfer of non-viral genetic material into eukaryotic cells. Infection/ Transduction- Transfer of viral genetic material into cells.

VHL and clear cell Renal Cell Carcinoma. Expression profiling reveals cell of origin. Renal Cell Carcinoma (RCC) Title. VHL syndrome hallmark cancer:

If and when cancer cells stop dividing, they do so at random points, not at the normal checkpoints in the cell cycle.

Chromosomes, Mapping, and the Meiosis Inheritance Connection

Lesson 3 Reading Material: Oncogenes and Tumor Suppressor Genes

SECOND PRIMARY BREAST CANCERS FOLLOWING HAEMATOLOGIC MALIGNANCIES A CASE SERIES STUDY FARAH TANVEER PGY 3 DR.MEIR WETZLER DR.

Breast cancer and normal cell lines

Malignant Lymphomas and Plasma Cell Myeloma

Psychoonkology, Sept lifestyle factors and epigenetics

mirnaselect pep-mir Cloning and Expression Vector

Molekylært målrettet medicinsk kræftbehandling for klinikere principper og metoder

Analysis and Integration of Big Data from Next-Generation Genomics, Epigenomics, and Transcriptomics

Immunologie für Studierende der Biologie & Molekularmedizin. mirna und Immunität. Jürgen Wittmann (jwittman@molmed.uni-erlangen.

Appendix 2 Molecular Biology Core Curriculum. Websites and Other Resources

Thermo Scientific DharmaFECT Transfection Reagents

Quantitative 1-Schritt-DNA-Methylierungsanalyse aus genomischer DNA

Monoclonal Antibodies in Cancer. Ralph Schwall, PhD Associate Director, Translational Oncology Genentech, Inc.

CD22 Antigen Is Broadly Expressed on Lung Cancer Cells and Is a Target for Antibody-Based Therapy

1 Mutation and Genetic Change

Human Genome Organization: An Update. Genome Organization: An Update

Viral Infection: Receptors

Cell Growth and Reproduction Module B, Anchor 1

Micro RNAs: potentielle Biomarker für das. Blutspenderscreening

Superior TrueMAB TM monoclonal antibodies for the recognition of proteins native epitopes

Transcription:

Regulation of telomeres by mirnas in human cancer Stefan Schoeftner, PhD LNCIB, Trieste stefan.schoeftner@lncib.it SIES Discutiamo Insieme Florence, 2.11.214

Shelterin components and telomerase are key players in human cancer Shelterin Telomerase Replicative immortality Telomere maintenance Shelterin TRF1 TRF2 POT1 TPP1 TINF2 Telomerase TERT DKC1 TERC TERRA Mouse models Progeria, Cancer Progeria, Cancer Progeria, Cancer Progeria, Cancer Progeria; Cancer Progeria; Cancer Progeria; Cancer Human Cancer Cancer Progeria Progeria; Cancer Progeria; Cancer Progeria; Cancer ICF Syndrome How is telomerase/shelterin function regulated in human cancer? Can we identify mirnas that control telomere function in human cancer?? - telo-mirnas -

Regulation of telomeres by mirnas in human cancer 1. mir-155 drives telomere fragility in human breast cancer Dinami et al. Cancer Research 214 2. Silencing of mir-296 and mir-512 releases TERT expression in basal type breast cancer Dinami et al. Manuscript in preparation

luciferase reporter activity A high-throughput approach to identify mirnas with targeting specificity for telomere regulators 1. 2. 3. mirna target prediction for 3 UTRs of TRF1, TRF2, POT1, TERT, DKC1 mir-vector library firefly renilla 3 UTR TRF1 transient transfection mirna/reporter HT luciferase reporter assay 2,5 2 TRF1 onco-mir-155 1,5 1,5

A role for TRF1 and mir-155 in human cancer TRF1, a telomere master regulator * Telomere repeat binding protein * Negative regulator of telomere length * Promoted telomere replication * Mitotic fidelity * Chromosome end protection *Telomere recombination TRF1 -/- TRF1 -/- TRF1-/- Cancer +* TRF1 -/- - Down-regulation in breast cancer - Deletion of TRF1 promotes cancer in the absence of tumorsuppression mir-155, a multipotent mirna BIC locus mir-155 mir155hg Oncomir in neoplastic disease leukemia, B-cell lymphoma breast, thyroid, colon,cervical, lung cancer Cardiovascular diseases Haematopoiesis Inflammation

control mir-155 control mir-155 Relative luciferase reporter activity (control set 1 ) control mir-155 antagomir-155 mir-155 targets a partially conserved sequence motif in the 3 UTR of TRF1 125 1 75 5 25 p=.1 p=.532 TRF1 actin TRF2 actin POT1 actin wt-trf1 3 UTR D mir-155 TRF1-3 UTR

expression (log base 2 scale) High mir-155 expression correlates with low TRF1 levels in luminal breast cancer mir-155 up-regulation in breast cancer TRF1 downregulation in breast cancer TRF1 high low TRF1 in samples with high mir-155 luminal cancer with reduced TRF1 levels 39% 28% 1% mir-155-33% 75% mir-155 +/++ tumor peritumoral tumor peri- tumor peritumoral tumoral luminal triple HER2 + 2 negative n=6 p=8.14e-5 p=.2 p=.2 mir-155 high TRF1 low High (3) Medium-low (2) Low (1) negative () 5% 25% % p=.3

Low TRF1 expression correlates with poor prognosis is luminal breast cancer Low TRF1 results in poor prognosis mir-155 target genes TRF1 low TRF1 high TRF1 low TRF1 high mir-155 dependent expression of TRF1 is part of a mir-155 signature that predicts poor distant metastasis free and relapse free survival in luminal breast cancer

control mir-155 sitrf1 mir-155 modulates telomere telomere structure and homeostasis mir-155 controls TRF1 abundance at telomeres mir-155 promotes telomere elongation p<,1 p<,1 control mir-155 telomere fluorecenece units (a.f.u.) 3 2 1 595 ± 64 N=3 n=2143 67 ± 88 N=3 n=243 663 ± 22 N=3 n=2213 C B A antagomir-155 +* mir-155 sitrf1 +*

Telomere fragility Telomere sister chromatid fusions mir-155 induces chromosomal aberrations T- loop and G-stacks: obstacles to DNA replication MCF-7 + mir-155 DNA pol 1 2 spontaneous loss of DNA sister chromatid fusions abnormally shaped telomeres multiple telomere signals telomere sister chromatid fusions

mir-155 drives telomere fragility in human breast cancer by targeting TRF1 mir-155 ONCO-miRNA +* mir-155 high TRF1 - low Breast Cancer proliferation/metastasis SOCS1 TP53INP1 Telomere maintenance Telomere instability (fragility, fusions) genomic instability poor prognosis Telomere maintenance Telomere +* fragility Telomere sister chromatid fusions Dinami et al. Cancer Research 214

normal basal luma lumb her2 normal basal luma lumb her2 expression (log base 2 scale) expression (log base 2 scale) hsa-mir-541 hsa-mir-637 hsa-mir-127-5p hsa-mir-16-1* hsa-mir-661 hsa-mir-68 hsa- hsa-mir-512-5p hsa-mir-1234 hsa-mir-491-5p hsa-mir-296-3p hsa-mir-423-5p hsa-mir-299-3p hsa-mir-532-3p hsa-mir-1323 hsa-mir-1275 hsa-mir-138 hsa-mir-76 hsa-mir-663 hsa-mir-548a-3p hsa-mir-548f hsa-mir-1249 hsa-mir-548e hsa-mir-1182 hsa-mir-1266 hsa-mir-548o hsa-mir-137 hsa-mir-632 hsa-mir-1268 luciferase reporter activity and mir-512-5p target htert and are down-regulated in breast cancer mir-vector library firefly renilla 3 UTR 4 3,5 3 2,5 2 1,5 1,5 htert - mir-512-5p - transient transfection mirna/reporter mir-512-5p

TERT and mir-296/mir-512 are relevant for basal type breast cancer htert signature mir-512-5p signature ALL TUMORS (DMSF) Expression low high Expression low high Expression low high htert logrank P=.49 signature logrank P=.45 mir-512-5p signature logrank P=.15 BASAL- TYPE (DMSF) Expression low high Expression low high basal Expression low high basal

si-con si-tert mir-con mir-512-5p Control mir-296 mir-512 mir-512 TRAP activity; controls set 1 mir-296 1 si-con si-tert 1 h.i. 1 5 25 h.i. 1 5 25 h.i. 1 5 25 TSR8 mir-con mir-512-5p Control and mir-512-5p are negative regulators of telomere length and mir-512-5p target htert and reduce telomerase activity Over-expression of mir-296 or mir-512 cause telomere shortening DAPI/ Telomere Telomere p<,1 p<,1 12 1 8 6 4 2 p=.2 p=.3 n=9 n=9 n=9 74nt 68nt 62nt 56nt 5nt 8312 ± 161.8 6432 N=1491 ± 14.7 n=65 N=1344 n=67 7163 ± 142.9 N=1378 n=7 S-IC

MCF-7 SK-BR-3 T-47D MDA-MB-231 MDA-MB-468 MDA-MB-157 expression normalized to RNU49 cell number (x1 4 ) MCF-7 SK-BR-3 T-47D MDA-MB-231 MDA-MB-468 MDA-MB-157 mir-512-5p expression normalized to RNU49 cell number (x1 4 ) Control mir-296 mir-512 mir-512 and mir-296 reduce proliferation by driving apoptosis in MDA-MB-231 cells 2 15 1 5 mir-512-5p 6 4 2 Reduced proliferation mir-control mir-512 antago-mir-512 MDA-MB-231 *** ** mir-296/512 induce apoptosis 1 3 6 PARP cleaved 15 125 1 75 5 25 6 4 2 mir-control mir-296 antago-mir-296 MDA-MB-231 ** ** MDA-MB-231 Caspase cleaved actin 1 3 6 luminal basal

DMSO TSA SAHA TSA+SAHA expression (untreated set 1 ) mir-512-5p expression normalized to RNU49 expression (untreated set 1 ) mir-512-5p expression (untreated set 1 ) Epigenetic silencing of mir-512 and mir-296 in basal type MDA-MB-231 cells DNMT mir-296 DNMT mir-512 8 6 4 2 6 5 4 3 2 1 p=.1 p=.6 p=.1 1 3 1 p=,7 p=.3 p=.4 - + - + - - + + mm 5-Aza TSA SAHA 12 1 8 6 4 2 3 25 2 15 1 5 p=.3 p=.3 p=.6 1 3 1 p=,1 p=,8 p=,3 - - + - - + + mm 5-Aza HDAC mir-296 HDAC mir-512 + TSA SAHA MDA-MB-231 (basal) DNMT MDA-MB-231 (basal) HDAC HDAC HDAC HDAC Silencing of mir-296/512 loci DNMT silent silent Silencing of mir-296/512 loci Expressed Expressed

htert expression normalized to actin (DMSO set 1 ) htert expression Epigenetic silencing of mir-512 and mir-296 in basal type MDA-MB-231 cells ensures htert expression HDAC X htert 1 8 6 4 2 p=,4 p=,4 p=,4 - - + - - + + + TSA SAHA HDAC 14 12 1 8 6 4 2 mirna TSA/ SAHA mir-512-5p p=.3 p=.9 con con antago- 1 2 296/512 3 - + + htert HDAC DNMTs mir-512-5p htert poor prognosis

A mirna network that underlies telomere regulation in human cancer telo-mirnas control telomeres HDAC DNMT Integrating telo-mirnas into hallmark features of cancer mir-512-5p mir-155 tumor-promotion +* a telo-mirna network to be discovered

Acknowledgements The Team: Roberto Dinami Rosanna Sestito Eleonora Petti Valentina Buemi Federica Cioffi Collaborators Giovanni Blandino IRE, Rome Reuven Agami, NKI Amsterdam Marcella Mottolese IRE Rome Mauro Giacca, ICGEB Trieste Maria A. Blasco CNIO, Madrid Roberta Benetti LNCIB, Trieste Claudio Schneider LNCIB, Trieste LNCIB, Area Science Park, Trieste University of Trieste

mir-512-5p htert luciferase reporter activity 12 1 8 6 p=.2 p=.6 p=.1 p=.5 12 1 8 6 p=.3 p=.1 4 4 2 2 + - + - + - + - - + - + - + - + Con-miR + - + - Con-miR - + - + mir-512-5p wt- 3 UTR D83-85 3 UTR D479-481 3 UTR D83-85, 479-481 3 UTR wt- 3 UTR D17-3 UTR